title: Outcomes of assisted reproduction treatment after dopamine agonist -cabergoline- for prevention of ovarian hyper stimulation syndrome.
abstract: BACKGROUND
  Release of vascular endothelial growth factor (VEGF) by ovaries in response to HCG administration is one of the main mechanisms of ovarian hyper stimulation syndrome. Since Dopamine/dopamine receptor2 (Dp-r2) pathway activity -mediated by VEGF/ Vascular endothelial growth factor receptor 2 (VEGFR- 2) signaling-, is associated with angiogenic events, dopamine agonists were used for the management of severe forms of OHSS. In order to assess the effects of Cabergoline on angiogenesis in the human endometrium, and subsequently its impacts on the implantation rate this study was conducted.
  
  
  METHODS
  This historical cohort study was conducted based on existing data of 115 patients (20-40 years) whom underwent assisted reproductive treatment (ART) and with a high probability for developing OHSS between March 2007 and September 2008. Forty five cases received Cabergoline were compared to 70 control subjects. The statistical methods used were: Unpaired t-test for continuous variables and the chi-square test (or Fisher's exact test if required) for categorical variables.
  
  
  RESULTS
  None of the patients (treatment or control group) developed OHSS. The etiologies of infertility and administration of GnRH agonist or antagonist protocols were similar in two groups (p>0.2). Number of transferred embryos and zygote intra-fallopian transfer (ZIFT) did not differ between the two groups (p≥0.06). Implantation rate in treatment (3.1%) and control (6.6%) subjects was similar (p=0.4). No significant difference was observed in fertilization rate, chemical, clinical and ongoing pregnancies between the two groups (p>0.5).
  
  
  CONCLUSIONS
  Cabergoline can be safely administered in ART protocols to prevent OHSS, without compromising ART outcomes.
authors: Assistant Professor of Obstetrics & Gynecology, Fellowship in infertility, Department of Infertility of Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran. shmovahedy@razi.tums.ac.ir.
authors: Shohreh
authors: S
authors: Movahedi
authors: Associate Professor of Obstetrics & Gynecology, Fellowship in Infertility, Department of Infertility, Tehran University of Medical Sciences, Tehran, Iran. ivfshariati69@gmail.com.
authors: Leili
authors: L
authors: Safdarian
authors: Professor of Obstetrics & Gynecology, Fellowship in infertility, Department of Infertility of Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran. aghahoseini@sina.tums.ac.ir.
authors: Marzieh
authors: M
authors: Agahoseini
authors: Professor of Obstetrics & Gynecology, Fellowship in infertility, Department of Infertility of Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran. ivfshariati69@gmail.com.
authors: Ashraf
authors: A
authors: Aleyasin
authors: Assistant Professor of Obstetrics & Gynecology, Fellowship in Minimally Invasive Gynecology Surgery (FMIGS), Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran. sepidehkhodaverdi@yahoo.com.
authors: Sepideh
authors: S
authors: Khodaverdi
authors: Obstetrician & Gynecologist, Endometriosis Research Center, Iran University of Medical Sciences, Tehran, Iran. sara_asadolla@yahoo.com.
authors: Sara
authors: S
authors: Asadollah
authors: MD, MPH, Postdoctoral Fellow, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL, USA. ali_kord2006@yahoo.com.
authors: Ali
authors: A
authors: Kord Valeshabad
authors: PHD in Clinical Laboratory Sciences, Department of Infertility of Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran. parvin.fallahi@yahoo.com.
authors: Parvin
authors: P
authors: Fallahi
authors: Master in Clinical Laboratory Sciences, Department of Infertility of Shariati hospital, Tehran University of Medical Sciences, Tehran, Iran. zahra.rezaeian2000@gmaile.com.
authors: Zahra
authors: Z
authors: Rezaeeian
keywords: Cabergoline; Dopamine agonist; Implantation rate; OHSS; Ovarian Hyper stimulation Syndrome